Discounted Cash Flow Rating

Buy

Return on Equity Rating

Neutral

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Buy

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Cyteir Therapeutics, Inc. Common Stock (CYT)

Pharmaceutical Preparations

https://www.cyteir.com

Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.

99 HAYDEN AVENUE, BUILDING B, SUITE 450
LEXINGTON, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/18/2021

Market Cap

108,714,262

Shares Outstanding

36,180,000

Weighted SO

35,998,068

Total Employees

N/A

Upcoming Earnings

N/A

Beta

0.0960

Last Div

0.0000

Range

1.65-3.19

Chg

-0.0700

Avg Vol

167616

Mkt Cap

108714262

Exch

NASDAQ

Country

US

Phone

857 285 4140

DCF Diff

-1.1257

DCF

4.1457

Div Yield

0.0000

P/S

0.0000

EV Multiple

0.5480

P/FV

0.8703

Div Yield %

0.0000

P/E

-3.5232

PEG

-0.0847

Payout

0.0000

Current Ratio

21.8869

Quick Ratio

21.6551

Cash Ratio

21.6522

DSO

0.0000

DIO

-7.4400

Op Cycle

0.0000

DPO

222.3261

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

0.0702

ROA

-0.2357

ROE

-0.2313

ROCE

-0.3059

NI/EBT

0.9298

EBT/EBIT

0.8683

EBIT/Rev

0.0000

Debt Ratio

0.0001

D/E

0.0001

LT Debt/Cap

0.0000

Total Debt/Cap

0.0001

Int Coverage

39.3955

CF/Debt

-1611.8125

Equity Multi

1.0478

Rec Turnover

0.0000

Pay Turnover

1.6417

Inv Turnover

-49.0588

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

-0.7158

FCF/Share

-0.7241

Cash/Share

3.5870

OCF/Sales

0.0000

FCF/OCF

1.0117

CF Coverage

-1611.8125

ST Coverage

-1611.8125

CapEx Coverage

-85.3940

Div&CapEx Cov

-85.3940

P/BV

0.8703

P/B

0.8703

P/S

0.0000

P/E

-3.5232

P/FCF

-4.1667

P/OCF

-4.2193

P/CF

-4.2193

PEG

-0.0847

P/S

0.0000

EV Multiple

0.5480

P/FV

0.8703

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Nov 23, 15:30 $HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of MKFG, CYTH, BRKH and CFB GlobeNewswire Inc. Nov 22, 22:40 $HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of CYTH, NAPA, MNTX and MARX GlobeNewswire Inc. Nov 20, 23:34 $HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of CYTH, VBFC, CFB and MKFG GlobeNewswire Inc. Nov 16, 14:00 Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024 GlobeNewswire Inc. Nov 16, 14:00 Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024 Investing.com Jul 19, 03:19 Insider Sale: Director Jens Holstein Sells 5,000 Shares of Veracyte Inc (VCYT) By GuruFocus - Investing.com Canada GlobeNewswire Inc. May 23, 03:30 Cytokinetics Announces Pricing of Public Offering of Common Stock GlobeNewswire Inc. Jan 18, 13:00 Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024 Benzinga Jan 12, 14:38 Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst MarketWatch Jan 09, 05:19 GSK to buy asthma drug developer for up to $1.4 billion in pipeline push GlobeNewswire Inc. Jan 08, 08:47 Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit The Motley Fool Jan 03, 06:45 2 Biotechs That Could Get Bought Out in 2024 GlobeNewswire Inc. Dec 29, 08:47 Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewswire Inc. Dec 29, 08:47 Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Benzinga Dec 28, 12:19 Cytokinetics' Drug Potential: Analyst Suggests Key Role Of Established Pharma For Potential Launch Benzinga Dec 28, 12:19 Cytokinetics' Drug Potential: Analyst Suggests Key Role Of Established Pharma For Potential Launch Benzinga Dec 28, 08:35 Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday MarketWatch Dec 27, 16:06 Dow Jones posts record close as stocks end mostly higher MarketWatch Dec 27, 16:06 Dow Jones posts record close as stocks end mostly higher MarketWatch Dec 27, 14:03 Dow Jones on track for record close as stocks nudge higher

Revenue Product Segmentation